What is Multiple Myeloma Phase I MEDI4736 Clinical Trial?

Category: Others

false

Multiple Myeloma Phase I MEDI4736 Clinical Trial is an open-label study to determine the usage of durvalumab alone, durvalumab with pomalidomide, or durvalumab with pomalidomide and dexamethasone in patients with multiple myeloma. Identifier: NCT02616640

Side effects

Side effects as an overall problem

Side effects as an overall problem
Severity Evaluations
Severe
1
Moderate
0
Mild
0
None
0

Commonly reported side effects and conditions associated with Multiple Myeloma Phase I MEDI4736 Clinical Trial

Side effect Patients
Nonspecific interstitial pneumonitis 1

Why patients stopped taking Multiple Myeloma Phase I MEDI4736 Clinical Trial

Multiple reasons could be selected

Reason Patients
Doctor's advice 1
Side effects too severe 1
See 1 patient who's stopped using Multiple Myeloma Phase I MEDI4736 Clinical Trial

Duration

Stopped using Multiple Myeloma Phase I MEDI4736 Clinical Trial

Duration Patients
1 - 6 months 1
Adherence
Adherence Evaluations
Always 1
Usually 0
Sometimes 0
Never taken as prescribed 0
Burden
Burden Evaluations
Very hard to take 0
Somewhat hard to take 1
A little hard to take 0
Not at all hard to take 0
Last updated:
There are no evaluations for Multiple Myeloma Phase I MEDI4736 Clinical Trial.